Life Sciences Research for Lifelong Health
lab photo hero

Klaus Okkenhaug

Klaus obtained his B.Sc. in Biochemistry from the University of Victoria, British Columbia, Canada, followed by a Ph.D. in Immunology from the University of Toronto, where he studied CD28 signalling in Rob Rottapel’s lab. In 1999, he moved to London, UK, where he joined Bart Vanhaesebroeck’s group at the Ludwig Institute for Cancer Research as a Postdoctoral Fellow, working on the role of p110δ in immune responses. Klaus joined the Laboratory of Lymphocyte Signalling Lab and Development at the Babraham Institute as a Group Leader in 2003.

01223 333726

Email Klaus

Latest Publications

Targeting PI3Kδ Function For Amelioration of Murine Chronic Graft-Versus-Host Disease.

Paz K, Flynn R, Du J

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons
1600-6143: (2019)

PMID: 30748099

The PI3K p110δ Isoform Inhibitor Idelalisib Preferentially Inhibits Human Regulatory T Cell Function.

Chellappa S, Kushekhar K, Munthe LA

Journal of immunology (Baltimore, Md. : 1950)
1550-6606: (2019)

PMID: 30692213

Regulatory T Cell Migration Is Dependent on Glucokinase-Mediated Glycolysis.

Kishore M, Cheung KCP, Fu H

Immunity
47 1097-4180:875-889.e10 (2017)

PMID: 29166588

Multi-tissue DNA methylation age predictor in mouse.

Stubbs TM, Bonder MJ, Stark AK

Genome biology
18 1474-760X:68 (2017)

PMID: 28399939

Targeting PI3K in Cancer: Impact on Tumor Cells, Their Protective Stroma, Angiogenesis, and Immunotherapy.

Okkenhaug K, Graupera M, Vanhaesebroeck B

Cancer discovery
2159-8290: (2016)

PMID: 27655435